First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
Breakthrough Therapy designation for pain associated with DPN granted by FDA
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Subscribe To Our Newsletter & Stay Updated
